

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/2011

<b>Name of entity</b>	<b>SIGMA PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>ABN 15 088 417 403</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Mark Robert HOOPER</b>
<b>Date of last notice</b>	09/09/2013

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	28/03/2014
<b>No. of securities held prior to change</b>	21,174,550  Ordinary Shares <span style="float: right;">4,496,864</span>  Shares allocated pursuant to the employee share plan <span style="float: right;">13,612</span>  Shares allocated pursuant to the loan funded long term incentive plan <span style="float: right;">15,779,881</span>  Short term incentive plan performance rights <span style="float: right;">884,193</span>
<b>Class</b>	Ordinary
<b>Number acquired</b>	6,848,292

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$4,074,733.74
<b>No. of securities held after change</b>	28,022,842  Ordinary Shares 5,082,530  Shares allocated pursuant to the employee share plan 13,612  Shares allocated pursuant to the loan funded long term incentive plan 22,628,173  Short term incentive plan performance rights 298,527
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	6,848,292 shares allocated pursuant to Sigma's loan funded long term incentive plan.  The performance conditions will be tested at the end of the performance period (31/01/2017).  Performance conditions under the short term incentive plan were met and 585,666 performance rights converted to ordinary shares.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

For personal use only

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

For personal use only